Blanchardstown, Dublin is to be the site of a new biopharmaceutical manufacturing facility for Mallinckrodt as part of a €45m investment that will see 45 highly-skilled jobs created, as well as 300 construction jobs.
Construction is expected to take up to two years at the facility in the College Business and Technology Park in the Dublin suburb and brings Mallinckrodt Pharmaceuticals’ investment in Ireland to more than €165m over the past 22 years.
The new state-of-the-art facility will include a two-storey manufacturing building, a three-storey administration building and additional areas for future investment on a 4.85 hectare site.
The company is one of the largest of its kind in the world and provides treatment options for patients with a wide variety of health conditions, particularly autoimmune and rare diseases, analgesia, neonatal critical care respiratory therapies, and central nervous system disorders.
Mallinckrodt currently employs more than 120 people at its existing manufacturing site and offices in Dublin and this creation of 45 skilled pharmaceutical jobs will be one of the largest single job creation events in its history in the country.
Mark Trudeau, CEO and president of Mallinckrodt, said at the launch event for the new facility: “We are proud to have had a significant presence in Ireland for over two decades, and today marks an important step for the company.
“Our Irish workforce has served as a tremendous asset to our global operations to date. We are particularly pleased to be making this sizeable capital investment today, continuing our long-standing operations in Ireland.”
Biopharma jobs image via Shutterstock
